Table 5 Median rank of treatments according to PASI 75 response in each of the five networks
Treatment | Median rank (95% CrI) | ||||
|---|---|---|---|---|---|
Licensed doses N = 69 | No previous biologic use (< 25%) N = 34 | PASI score ≤ 25 N = 59 | Weight ≤ 90 kg N = 27 | ≥ 90% white patients N = 42 | |
Adalimumab | 11 (8–14) | 11 (8–12) | 10 (7–12) | 9 (5–11) | 10 (7–12) |
Apremilast | 17 (16–18) | 15 (14–16) | 16 (15–16) | 14 (13–14) | 16 (15–16) |
Brodalumab | 3 (1–6) | 4 (1–7) | 3 (2–5) | 2 (1–4) | 4 (2–6) |
Certolizumab 200 mg | 13 (9–15) | 8 (2–13) | 12 (9–12) | 11 (7–12) | 12 (8–13) |
Certolizumab 400 mg | 10 (7–13) | 6 (1–11) | 9 (7–11) | 8 (5–11) | 9 (6–11) |
DMF | 18 (17–18) | 16 (14–16) | 17 (17–17) | – | 17 (17–17) |
Etanercept 25 mg | 16 (15–17) | – | 14 (14–15) | – | 14 (13–16) |
Etanercept 50 mg (twice per week) | 15 (14–15) | 13 (12–13) | 13 (13–13) | 12 (11–12) | 13 (12–14) |
Etanercept 50 mg (once-weekly) | 14 (10–16) | 14 (14–15) | 15 (14–16) | 13 (13–14) | 15 (13–16) |
Guselkumab | 2 (1–6) | 3 (1–7) | 2 (2–5) | – | 6 (2–12) |
Infliximab | 5 (2–8) | 3 (1–7) | 6 (3–7) | 6 (3–10) | 5 (3–9) |
Ixekizumab | 1 (1–4) | 1 (1–4) | 1 (1–1) | 1 (1–5) | 2 (1–3) |
Risankizumab | 4 (1–8) | – | – | – | – |
Secukinumab | 4 (2–7) | 5 (2–7) | 4 (2–6) | 3 (1–5) | 1 (1–3) |
Tildrakizumab | 7 (4–12) | 7 (4–9) | 5 (3–7) | 4 (2–7) | 4 (3–7) |
Ustekinumab 45 mg | 10 (8–13) | 11 (8–12) | 9 (8–12) | 8 (5–11) | 9 (6–12) |
Ustekinumab 45 mg/90 mg | 11 (8–14) | 10 (7–12) | 10 (7–12) | 8 (5–11) | 10 (6–12) |
Ustekinumab 90 mg | 8 (5–10) | 9 (7–12) | 7 (6–8) | 6 (1–11) | 7 (5–9) |
Total number of treatments | 18 | 16 | 17 | 14 | 17 |